Latest news with #DELTA
Bangkok Post
4 days ago
- Business
- Bangkok Post
Trump tariff drama could depress SET in second half
The Stock Exchange of Thailand (SET) index reached a new low for the year in June, trading in a range between 1,053.79 and 1,149.68 points, and ending the month at 1,089.56, down 59.62 points or 5.2% from the month before. Several factors influenced the market's direction. First, investors worried about a new 10% cap on the weighting of individual shares in key indices, in order to reduce the outsized influence of trading in firms such as DELTA, which accounts for 13% of the SET100. Passive funds correlated to the SET would need to adjust their holdings, which could lead to a DELTA sell-off. As it turned out, the effective date of the change has not yet been announced. Fear of an escalating war between Israel and Iran also weighed on investors, though a subsequent ceasefire appears to be holding. In addition, very few countries have reached trade agreements with the US ahead of its July 9 tariff deadline, but President Donald Trump again moved the deadline to Aug 1, though the urgency of talks remains for countries such as Thailand. Meanwhile, the border dispute between Thailand and Cambodia raised political and economic concerns, pushing the SET index to its lowest point of the year at 1,053.79 points. Average trading volume for the month was 39.2 billion baht, down 8.5% from May. We began July with hopes that negotiations with the US would reduce Thailand's tariff rate from 36%. Vietnam reached a deal with the US for a rate of 20%, while allowing all US goods imports with zero tax. However, July 9 came and went, and a letter from Trump informed Thailand it still faced a 36% tariff if a deal is not agreed by Aug 1. Trump also threatened any country that supports ideas advanced by the BRICS group with an additional 10% tariff hike. Thailand became a partner country of BRICS this year. As it stands, Thailand's tariff rate is higher than those proposed for its neighbours and direct competitors in many export categories: Malaysia (25%), Vietnam (20%), Japan and South Korea (25%) and India (26%). If we cannot negotiate the rate down to 20-25%, in the long term we may lose production centres or foreign direct investment. In the worst case, GDP growth next year could be less than 1%. Meanwhile, political uncertainty continues to depress the market. The exit of the Bhumjaithai Party from the coalition leaves it with a slim majority, and the suspension of PM Paetongtarn Shinawatra complicates matters further. A final Constitutional Court ruling on her fate will take a few weeks, with premature dissolution of the House the worst-case scenario. INVESTMENT STRATEGY Our investment strategy for this month is to avoid export-related stocks and focus mainly on domestic plays and stocks with good second-quarter earnings expectations. We picked Advanced Info Service (ADVANC), Bangkok Asset Management (BAM), Gulf Development (GULF) and Prima Marine (PRM). We forecast second-quarter net profit for ADVANC of 10.9 billion baht, up 3.2% quarter-on-quarter and 27.3% year-on-year. The good result will come from adjusted prepaid packages, net subscriber additions and a decline in operating expenses due to fully appreciated assets and lower utilities expenses. The mobile operator just won an auction for the 2100 megahertz spectrum and this will help reduce costs starting from August. Moreover, its new English Premier League football broadcast package received a good response from the market with a lower package price than previous operator True. This will add further upside for its fibre business. ADVANC is always a good dividend stock with around a 5% yield per year. BAM announced recently it sold non-performing assets of 1.4 billion baht and special-mention non-performing loan collections worth 2.8 billion. These gains will be realised in the second quarter and will boost its profit, exceeding our expectations. We upgraded our profit forecast for 2025 by 90%. The improved result could lead to a better dividend. With a dividend payout policy of 70% of net profit, we could expect a dividend of 0.64 baht per share for this year, a yield of almost 10%. Moreover, the lower interest rate environment will benefit BAM's operations. We recommend GULF mainly based on its good fundamentals and its share price dropping 15% the past two months. GULF just purchased a 50% stake in nine solar projects from GUNKUL, totalling 461MW. The increase in net asset value from these projects will be minimal at just 0.1 baht per share, given its total power portfolio of 13.2GW. Still it is a positive trend, as more projects will help profits continue to grow. PRM is another golden stock we have always preferred. Its fleet has come back to full service in the second quarter and it plans to add more ships in the third quarter. The Thailand-Cambodia dispute is not affecting its offshore oilfield services, as its services to OR are just 15-18 rounds per month, and it can always redirect to Singapore or Vietnam instead. PRM is also one of the best dividend stocks with a projected yield of more than 10% per year for the next three years.
ME Construction
17-06-2025
- Business
- ME Construction
DELTA Coatings International starts construction on new facility in Dubai
Construction DELTA Coatings International starts construction on new facility in Dubai By The hub will feature open-plan workspaces for collaboration amongst DELTA's growing international team, and will showcase the firm's polyurea based coatings through customer engagement areas DELTA Coatings International has officially commenced construction on its new headquarters and manufacturing facility at Dubai Industrial City (DIC). This eco-friendly development signifies a pivotal moment in DELTA Coatings' strategic growth plan, aiming to substantially expand production and foster innovation. The groundbreaking ceremony was attended by senior representatives from DELTA Coatings International and Dubai Industrial City, including Saud Abu Al-Shawareb, Managing Director of Dubai Industrial City; Abdulla Alraeesi, Assistant Manager of Business Development at Dubai Industrial City; Saleem, Chairman and Founder of DELTA Coatings International; Sami Saleem, Chief Executive Officer; Belvin Marx, General Manager and Paul Symmons, Business Development Manager. The new plant will be partially powered by renewable energy, including a substantial rooftop solar panel installation. This initiative aligns with the company's ongoing sustainability and decarbonisation efforts. Once operational, the facility will significantly increase DELTA Coatings' existing manufacturing output by tripling it, while also tripling its warehouse space. This expansion will enable the company to better meet the surging global demand for its DELTAShield product range, a statement highlighted. 'Our new global HQ and plant represents a pivotal moment in DELTA Coatings' evolution since its inception over 20 years ago,' said Belvin Marx, General Manager at DELTA Coatings International. 'With growing awareness of polyurea's superior durability and increased demand globally, the new plant will empower our teams to innovate and deliver even greater value to our clients and partners globally. From demonstrating the performance benefits of polyurea coatings and waterproofing to training the next generation of applicators, this facility is designed to inspire and support market leadership.' The hub will feature modern, open-plan workspaces that facilitate collaboration among DELTA's growing international team. It will also include customer engagement areas that showcase the strength and versatility of polyurea-based coatings. The plant will triple its current manufacturing output and warehouse space, with scalable infrastructure to accommodate continued growth and meet increasing product demand, the firm said. The site will also house a R&D Centre of Excellence. This advanced laboratory will focus on developing next-generation polyurea products that are tailored to challenging regional climates and client-specific needs. This will ensure that DELTA Coatings remains an international leader in innovation. The new facility, scheduled for completion and commissioning in December 2025, is situated in Dubai Industrial City. It offers access to key markets across the GCC and beyond, just a 20-minute drive from Dubai World Central Airport and Jebel Ali Port, and within a 45-minute drive of Abu Dhabi. A Graco HPCF equipment training hub will be established within the facility, serving as a regional centre for demonstrations of HPCF spray equipment, rapid maintenance and repair services, and hands-on training programs for coating applicators. A high-efficiency warehouse and distribution centre will be integrated with electronic stock management systems to optimise inventory control and guarantee reliable, timely product deliveries.
Business Wire
03-06-2025
- Health
- Business Wire
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle in the treatment of adults with mild to severe Palmoplantar Pustulosis (PPP). PPP is the first disease for which LEO Pharma will investigate delgocitinib cream since completion of the Phase 3 DELTA trials in Chronic Hand Eczema (CHE). ' The DELTA NEXT trial in PPP represents an exciting new chapter in the clinical development journey of delgocitinib cream,' said Christophe Bourdon, Chief Executive Officer, LEO Pharma. 'PPP is a disease with few treatment options that can severely affect quality of life. We are hopeful that this therapy could potentially provide much-needed help for patients suffering from this devastating condition.' PPP is an uncommon, chronic, inflammatory, relapsing skin disease characterized by repeated episodes of sterile pustules alongside erythema, blistering and scaly skin on the palms and/or soles of the feet. 3,4 PPP is associated with a high patient burden, resulting in significant impairment of quality of life. Patients often experience pain, fatigue, and the condition can be triggered by factors such as smoking, infections, and stress. PPP is associated with comorbidities such as thyroid dysfunction and metabolic syndrome. 4 There are currently no approved advanced systemic treatments for PPP in the U.S. or Europe. 5 PPP is associated with complex T-cell activation patterns, which may be why many biologics that target individual T helper cell populations have shown limited efficacy in clinical trials. 6 Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor shown to inhibit the activity of all four JAKs, which are involved in inflammatory signaling. 1,2 Using delgocitinib cream's mechanism of action, the trial will investigate the potential benefit of inhibiting multiple JAKs to treat PPP. 'I've seen firsthand how PPP can severely disrupt patients' lives, making it painful to walk, perform activities of daily living and impacting their ability to work,' said Dr. Robert Bissonnette, international coordinating investigator (ICI) on the DELTA NEXT trial and Chairman at Innovaderm Montreal, Canada. 'Despite the significant burden it places on patients, treatment options remain limited. There is a real and urgent need for effective therapies." The DELTA NEXT trial plans to recruit up to 135 patients with active, chronic, mild to severe PPP for whom topical corticosteroids are inadequate or inadvisable. Participants will be recruited across 40-45 sites in the United States, Canada, the United Kingdom, Germany, and Poland. Currently, delgocitinib cream is approved for adults in the European Union, United Kingdom, Switzerland, and the United Arab Emirates for the treatment of moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate, and is under review in other markets, including the United States. For more information on the DELTA NEXT trial, go to Notes to editors About Delgocitinib Cream Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor. It prevents the activation of the JAK-STAT pathway by blocking the signaling of several inflammatory cytokines, thereby suppressing the inflammatory cascade and preventing the downregulation of important barrier genes. 7 Delgocitinib cream is currently approved in the European Union, the United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. It is under review in other markets, including the United States. In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib cream for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. About the DELTA NEXT Trial DELTA NEXT is a phase 2a, randomized, double-blind, two-arm, vehicle control, adaptive design proof-of-concept trial to assess the efficacy and safety of twice-daily delgocitinib cream compared with cream vehicle in adult subjects with mild to severe PPP. The DELTA NEXT trial plans to recruit up to 135 patients with active, chronic, mild to severe PPP for whom topical corticosteroids are inadequate or inadvisable. Participants will be randomized into a 2:1 ratio to receive either delgocitinib cream or cream vehicle. Participants will be recruited across 40-45 sites in the United States, Canada, the United Kingdom, Germany, and Poland. About Palmoplantar Pustulosis (PPP) Palmoplantar Pustulosis (PPP) is an uncommon chronic, inflammatory, relapsing skin disease characterized by repeated episodes of sterile pustules alongside erythema, blistering and scaly skin on the palms and/or soles of the feet. 3,4 The disease is more common in females, with the estimated prevalence ranging from 0.01% to 0.05%. 3,4 The mean age of patients ranges from 40 to 58 years and is often associated with smoking, thyroid-gland abnormalities, and nickel sensitivity. 4,8 PPP is associated with a significant clinical burden. Patients often experience pain, fatigue, and the condition can be associated with hyperlipidemia and high blood pressure. 8 The condition has been shown to have a greater impairment on work and daily life than plaque psoriasis. 8 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit References Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41-51. Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. Exp Dermatol. 2018;27(1):22-29. Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252. Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments. Am J Clin Dermatol. 2020;21(3):355-370. Xu JM, Wang HM, Jin HZ. An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations. Expert Rev Clin Immunol. 2023;19(5):499-516. McCluskey D, Benzian-Olsson N, Mahil SK, et al. Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol. 2022;150(4):882-893. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [published correction appears in Ther Clin Risk Manag. 2021 Mar 18;17:233.]. Ther Clin Risk Manag. 2020;16:1319-1332. Lebwohl MG, Medeiros RA, Strober B, et al. Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry. J Psoriasis Psoriatic Arthritis. 2023;8:56–65.
Malaysian Reserve
26-05-2025
- Automotive
- Malaysian Reserve
Charge Into The Cold: EcoFlow Launches EOFY Sale
SYDNEY, May 26, 2025 /PRNewswire/ — As Aussies prepare for winter getaways and school holidays road trips, EcoFlow is offering limited-time End of Financial Year (EOFY) savings on its popular DELTA series of portable power solutions and accessories. The EcoFlow DELTA series is designed to handle heavy-duty power needs – offering fast charging, large battery capacity and enough output to run appliances, power tools and entertainment gear. Whether you're braving the cold outdoors or need extra power for backyard entertaining, these winter-ready essentials deliver power when and where you need it most. With discounts of up to 33%, EcoFlow's EOFY sale includes high-capacity portable power stations and vehicle-ready alternator charging bundles, perfect for 4WDs, RVs and caravans. On sale from today (May 26) to June 30: EcoFlow DELTA 2 Max + 800W Alternator Charger – Now $2,599, originally $3,198 (19% off) EcoFlow DELTA Pro 3 – Now $4,599, originally $4,999 (8% off) EcoFlow 800W Alternator Charger – Now $549, originally $599 (8% off) On sale from June 12 to June 30: EcoFlow DELTA Pro – Now $2,999, originally $4,499 (33% off) EcoFlow DELTA 2 + 800W Alternator Charger – Now $1,599, originally $1,798 (11% off) EcoFlow DELTA 2 – Now $1,099, originally $1,199 (8% off) Choosing the right power this winter EcoFlow's DELTA series offers flexible power solutions to suit your winter needs. According to recent EcoFlow data, the average daily energy consumption varies significantly across models: EcoFlow DELTA Pro (120.9kWh) and EcoFlow DELTA Pro 3 (118.0kWh) are top performers, which makes them ideal for portable heaters, induction cooktops or multiple appliances during long road trips. EcoFlow DELTA 2 (37.8kWh) and EcoFlow DELTA 2 Max (35.7kWh) are perfect for charging smaller devices, running lights or powering small fridges on weekend getaways. The EcoFlow EOFY sale runs until June 30, 2025, while stock lasts. To learn more or shop the full range, visit here. New Product Launch: EcoFlow 500W alternator charger now available Following the success of its 800W Alternator Charger, EcoFlow has expanded its vehicle charging lineup with the launch of a new 500W version – just in time for winter road trips. The EcoFlow 500W Alternator Charger offers a more compact and cost-effective option for users with smaller power needs, making it an ideal match for the EcoFlow RIVER series and the EcoFlow DELTA 2 when paired with the XT150 cable. Like its larger counterpart, the 500W model allows you to recharge your portable power station directly from your vehicle's alternator while charging, giving users more flexibility to stay powered on the go, without needing to stop and plug into a wall socket or rely on solar. About EcoFlowEcoFlow is a leading provider of eco-friendly energy solutions, committed to powering a new world. Since its founding in 2017, EcoFlow has aimed to be the FIRST in power solutions — Flexible, Innovative, Reliable, Simple, and Thorough — for individuals and families, whether at home, outdoors or on the go. With a smart manufacturing center in China, and headquarters in the USA, Germany and Japan, EcoFlow has empowered over 4.5 million users in 140 markets worldwide. For more information, visit Media ContactAllison Worldwide for EcoFlow Australiaecoflowanz@
Sassy Mama
20-05-2025
- General
- Sassy Mama
Is Your Child Ready For P1? Build Their Confidence With 1-On-1 Or Small Group English Lessons
Looking for a way to help your child learn to read before Primary 1? Discover how British Council's 1-on-1 and small group English lessons help students thrive at their upcoming Open House! Starting Primary 1 is a big milestone! Preparing your child for this crucial transition can be exciting if you have the right support. That's why British Council is here to support your child with personalised 1-on-1 and small group private English lessons for kids that will lay the essential foundation they need so they will be ready to speak, read and write confidently when they start Primary 1. Customised English lessons by experienced teachers British Council's 1-on-1 and small group private English lessons for kids equip them with the tools and practice they need to read fluently. Kids as young as Kindergarten 1 can join their English enrichment courses. Lessons are fully customised to meet your child's needs and delivered by highly experienced and qualified teachers who hold University of Cambridge CELTA or DELTA qualifications. Understanding that each child is different, the English teacher tailors each lesson to your child's pace with effective and trusted resources, including materials aligned with the syllabus set by the Singapore Ministry of Education (MOE). Pre-schoolers are engaged with active learning with lots of hands-on exploration to develop your child's speaking confidence and socialisation skills. Whether you want your child to study with one or two friends, have lessons at our centres or prefer the convenience of learning from home, British Council offers a variety of instruction methods to suit your busy schedule. When your child first begins, their teacher will assess their current level and provide feedback and insight into the course content, as well as a post-course consultation to track their progress. British Council also offers English lessons for teens and adults, because learning is a lifelong journey. Register for their upcoming Open House If your child is entering Primary 1 in January 2026, don't miss the British Council Young Learners Open House! Register for their Open House to get a glimpse of how they instil a love of the English language through their engaging, interactive lessons. Take a deep dive into their curriculum and teaching methods, and get all of your burning questions answered by their friendly Academic team. Enjoy an exclusive discount of $100 off when you register at the Open House for a 10-hour package for their 1:1 or small-group lessons for kids, teens or adults. British Council, 30 Napier Road, Singapore 258509 and 480 Lorong 6 Toa Payoh, #09-01 HDB Hub, East Wing, Singapore 310480 (or at a location of your choice!), Read more: Best English Tuition Centres In Singapore
